Cancers, Free Full-Text

Imatinib became the standard treatment for chronic myeloid leukemia (CML) about 20 years ago, which was a major breakthrough in stabilizing the pathology and improving the quality of life of patients. However, the emergence of resistance to imatinib and other tyrosine kinase inhibitors leads researchers to characterize new therapeutic targets. Several studies have highlighted the role of histone deacetylase 6 (HDAC6) in various pathologies, including cancer. This protein effectively intervenes in cellular activities by its primarily cytoplasmic localization. In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML.

I Am Cancer Free! - Cancer Free Gift - Tapestry

Kidney Cancer: Symptoms, Signs, Causes & Treatment

8 Ways to prevent cancer & be healthy -Siteman Cancer Center

Free PSD Breast cancer awareness editable text effect

Profiling molecular regulators of recurrence in chemorefractory triple-negative breast cancers, Breast Cancer Research

from Flow Cytometry to Cytomics, Page 2

American Cancer Society

Kidney Cancer Text · Free Stock Photo

Free Samples For Patients - Colaboratory

Cancer Awareness Month Calendar & Ribbon Color

Radical causes of cancer

Cancer-immune interactions in ER-positive breast cancers: PI3K pathway alterations and tumor-infiltrating lymphocytes, Breast Cancer Research

Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study.